Geron Corporation (GERN)
After hours:
| Previous close | 3.5000 |
| Open | 3.5500 |
| Bid | 3.5600 x 3900 |
| Ask | 3.5900 x 2900 |
| Day's range | 3.5100 - 3.7090 |
| 52-week range | 1.6400 - 4.0500 |
| Volume | |
| Avg. volume | 12,884,327 |
| Market cap | 2.108B |
| Beta (5Y monthly) | 0.61 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3200 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.08 |
Business WireGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., April 18, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Simply Wall St.Geron Corporation (NASDAQ:GERN) Is Expected To Breakeven In The Near Future
We feel now is a pretty good time to analyse Geron Corporation's ( NASDAQ:GERN ) business as it appears the company may...
Business WireGeron to Participate at Upcoming Investor Conferences in April
FOSTER CITY, Calif., April 03, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences:
